ArticleJournal for immunotherapy of cancer2025

Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refractory tumor models.

Francesca Rosato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.